SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2004 ENCYSIVE PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) <Table> DELAWARE 0-20117 13-3532643 (State of Incorporation) (Commission File Number) (IRS Employer Identification No.) </Table> 6700 WEST LOOP, 4TH FLOOR BELLAIRE, TEXAS 77401 (Address of Registrant's principal executive offices) (713) 796-8822 (Registrant's telephone number, including area code) Not Applicable (Former name or former address, if changed since last report) ITEM 5. OTHER EVENTS AND REGULATION FD DISCLOSURE On August 2, 2004, Encysive Pharmaceuticals Inc. issued a press release announcing that that William R. Ringo resigned from the Company's Board of Directors following his appointment as Chief Executive Officer of Abgenix, Inc. Mr. Ringo has served as a member of the Board since October of 2001. His departure reduces the number of directors to 10. [SIGNATURE PAGE FOLLOWS] SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Encysive Pharmaceuticals Inc. Date: August 2, 2004 By: /s/ Stephen L. Mueller ---------------------- Stephen L. Mueller Vice-President, Finance and Administration Secretary and Treasurer